In Brief: Tavist-D caplets
This article was originally published in The Tan Sheet
Executive Summary
Tavist-D caplets: Novartis Consumer Health's clemastine fumurate/phenylpropanolamine product approved for the common cold in extended release caplet form Oct. 17. The supplemental application for caplets (NDA 20-640) was filed by the company May 22. Tavist-D capsules and tablets were approved for the cold indication on Oct. 31, 1996 ("The Tan Sheet" Nov. 4, 1996, In Brief)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning